Zacks Investment Research
Mon, Mar 23rd, 2026
Most Recent Stories
Gold prices capped their steepest weekly loss in 15 years as investors assessed the economic fallout from the escalating U.S.-Iran conflict. For the week, gold tumbled 9.6% — its biggest drop since September...
For Immediate ReleaseChicago, IL – March 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
For Immediate ReleaseChicago, IL – March 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
For Immediate ReleaseChicago, IL – March 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
For Immediate ReleaseChicago, IL – March 23, 2026 – Stocks in this week’s article are NVIDIA Corp. NVDA and Micron Technology, Inc. MU.Top 2 Profitable Stocks to Buy Right Now (NVDA, MU)Investors...
For Immediate ReleaseChicago, IL – March 23, 2026 – Today, Zacks Investment Ideas feature highlights Micron Technology MU, FedEx FDX, Nvidia NVDA, H World Group Ltd. HTHT, Alibaba BABA and Five Below...
For Immediate ReleaseChicago, IL – March 23, 2026 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the...
Strong quarterly results from Micron Technology MUÂ and FedEx FDXÂ stood out as rare bright spots in an otherwise turbulent week, as broader equity indexes retreated sharply amid surging oil prices and...
AppLovin APP has spent years building an AI-driven ad stack around its Axon engine and a unified marketplace that matches advertiser demand with publisher supply. Now management is pushing that same playbook...
Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with active psoriatic arthritis (PsA). The decision adds a second major indication...
